

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 4, 2026

XERIS BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-40880 (Commission File Number)	87-1082097 (I.R.S. Employer Identification No.)
---	--	---

**1375 West Fulton Street, Suite 1300
Chicago, Illinois 60607**
(Address of principal executive offices, including zip code)

(844) 445-5704
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	XERS	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 4, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on April 14, 2026, the record date for the Annual Meeting, there were 172,625,762 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting, of which 128,268,073 shares were present in person virtually or represented by proxy at the Annual Meeting, constituting a quorum on all matters voted upon. Shares present virtually during the Annual Meeting were considered shares represented in person at the Annual Meeting. The final voting results of the Annual Meeting are as follows:

Proposal One: Election of Directors

As described in the Company’s Definitive Proxy Statement on Schedule 14A, filed on April 23, 2026 (the “Proxy Statement”), the Company’s Board of Directors nominated two individuals to serve as Class II directors until the Company’s 2029 Annual Meeting of Stockholders, or until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal. Each nominee was elected by a plurality vote in accordance with the Company’s Amended and Restated Bylaws, as follows:

Class II Director Nominee	For	Withhold	Broker Non-Votes
Dawn Halkuff	62,581,577	24,906,166	40,780,330
John Johnson	52,665,077	34,822,666	40,780,330

Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:

For	Against	Abstain	Broker Non-Votes
125,789,818	1,032,530	1,445,725	—

Proposal Three: Advisory Vote to Approve Named Executive Officer Compensation

The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the “Say-on-Pay Vote”). The Company’s stockholders voted as follows to approve such executive compensation for the Company’s named executive officers pursuant to the Say-on-Pay Vote:

For	Against	Abstain	Broker Non-Votes
82,230,204	4,658,035	599,504	40,780,330

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 5, 2026

Xeris Biopharma Holdings, Inc.

By: /s/ Steven M. Pieper

Name: Steven M. Pieper

Title: *Chief Financial Officer*